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SUMMARY
This study aimed to evaluate possible discrepancies in waitlist outcomes
between liver diseases, including alcohol-related liver disease (ALD), nonalcoholic steatohepatitis (NASH), hepatitis C virus infection (HCV), primary
biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Patients
registered for liver transplantation from January 11, 2016, to June 30,
2018, were evaluated using OPTN/UNOS registry. Waitlist outcomes were
compared between the five-disease groups. Patients were categorized by
initial MELD-Na-score (6–20, 21–29, and ≥30) to identify outcome variations. Prognostic impact of transplantation was assessed according to final
MELD-Na scores using Cox regression analysis modeling transplantation
as a time-dependent covariate. 6053 with ALD, 3814 with NASH, 1558
with HCV, 602 with PBC, and 819 with PSC were eligible. Compared to
ALD with comparable MELD-Na-scores, NASH with lower [adjusted hazard ratio (aHR) = 1.30, P = 0.042] and mid-scores (aHR = 1.35,
P = 0.008) showed significantly higher risk of 1-year waitlist mortality, and
PBC with higher scores showed significantly higher risk of 90-day
(aHR = 1.69, P = 0.03) and 1-year waitlist mortality (aHR = 1.69,
P = 0.02). Positive prognostic impact of transplantation was not seen until
score of 24–27 in ALD, 18–20 in HCV, 15–17 in NASH, and 24–27 in
PBC and PSC. There are significant differences in waitlist outcomes among
etiologies, which may differ the optimal transplant timing.
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Introduction
In the United States, all adult liver transplant (LT) candidates are ranked based on a Model for End-Stage
Liver Disease-Sodium (MELD-Na) score regardless of
liver disease etiology, unless they meet criteria for
exception scores [1–3]. In patients with alcohol-related
liver disease (ALD), there may be less ongoing hepatic
ª 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd
doi:10.1111/tri.13814

injury during the waiting period because of mandatory
alcohol abstinence [4,5], whereas liver damage may progress in patients with other chronic liver diseases
including
nonalcoholic
steatohepatitis
(NASH),
untreated hepatitis C virus (HCV) infection, primary
biliary cholangitis (PBC), and primary sclerosing
cholangitis (PSC). However, disease-specific characteristics are not taken into consideration in the current liver
499
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allocation system. Because the MELD-Na score system
does not distinguish liver disease etiology, current liver
allocation may not stratify patient medical urgency
accurately [6].
We hypothesize that disease progression in liver
transplant candidates might differ according to liver disease etiology, and risk stratification might need to be
altered in the allocation system based on disease and
patient characteristics. This study aims to evaluate possible difference of disease progression and discrepancies
in waitlist outcomes between major liver disease groups,
including ALD, HCV, NASH, PBC, and PSC, and to
explore better risk stratification among liver transplant
candidates.

Methods
Study population
The Organ Procurement and Transplantation Network/
United Network for Organ Sharing (OPTN/UNOS) registry was used to obtain data for this study. All adults
(≥18 years) registered for liver transplantation from January 11, 2016, to June 30, 2018, under the MELD-Na
score-based allocation system were evaluated. Primary
and secondary liver disease etiology was reviewed and
five major groups, ALD, NASH, HCV, PBC, and PSC,
were evaluated. Patients with overlapping diseases, in
which two of the five diagnoses were recorded, were
excluded. Patients with alcoholic hepatitis were not
included in the ALD group. Patients with MELD exception for hepatocellular carcinoma (HCC) and other reasons (non-HCC condition) were evaluated separately.
Other exclusion criteria included the following: liver
transplantation combined with thoracic organ(s), pancreas, and/or intestine; Status 1A; registration for retransplantation.
This study used the Standard Transplant Analysis and
Research file provided by the OPTN/UNOS in which all
individually identifiable information is encrypted. Henry
Ford Institutional Review Board (IRB) exempted IRB
approval to conduct this study using this database.

Analysis for waitlist outcomes
Waitlist outcomes including mortality, liver transplantation, or recovery (too well for transplantation) were
studied. Removal from waitlist due to clinical deterioration (too sick for transplant) was included in mortality.
Mortality, transplantation, recovery, and removal from
waitlist for other reasons were considered competing
500

risk events. Patients who were still active on the waitlist
and those who received living donor liver transplant
were censored. Patients who did not receive MELD
exceptions were categorized into three groups, according
to initial MELD-Na score at listing (score of 6–20, 21–
29, and ≥30), and 90-day and 1-year waitlist outcomes
were compared among the five etiologies. Risks were
adjusted for UNOS region (1 through 11) and recipient
characteristics at registration, including age, gender,
race, body mass index, diabetes, ascites, encephalopathy,
Karnofsky score, life support use, and registration for
liver–kidney transplantation. Another multivariable Cox
regression model was created in each etiology group to
determine risk factors for 90-day and 1-year waitlist
mortality. Patients who received MELD exceptions for
hepatocellular carcinoma (HCC) and non-HCC were
separately analyzed and initial MELD-Na score was
included in the risk adjustment. For patients with HCC
exception, 180-day and 1-year waitlist outcomes were
assessed, because of mandatory 6-month waiting rule
before being granted for an exception score [7]. For
those with MELD exception for other reasons, 90-day
and 1-year outcomes were evaluated.

Disease progression according to underlying liver
disease etiologies
To assess disease progression, delta MELD-Na score,
change in status of ascites, encephalopathy and dialysis
requirement were assessed. Delta MELD-Na score was
calculated by dividing the change in score by the interval between reported dates of change [6,8]. The STAR
waitlist database was queried for initial laboratory
MELD-Na scores at listing, and we further identified
MELD-Na scores at the closest date to 90 days after listing using STAR waitlist history database. Delta MELDNa score was calculated only when patients were listed
over 14 days. We estimated the 90-day average delta
MELD-Na.
• 90-day average Delta MELD-Na = (MELD-Na score
recorded on the day closest to 90 days after listing –
initial MELD-Na score) 9 90 days/Day difference
between two points
Patients were dichotomized at 90-day average delta
MELD-Na of 15 (30-day average MELD-Na of 5) which
is considered as a cut-off value associated with higher
waitlist mortality [9].
Status of ascites, encephalopathy, and dialysis requirement at registration were obtained. We identified
patients who newly developed moderate ascites, grade 3
or 4 encephalopathy, and/or required dialysis within
Transplant International 2021; 34: 499–513
ª 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd

Disease-specific liver waitlist outcomes

90 days after registration. Delta MELD-Na, ascites,
encephalopathy, and dialysis status were compared
between liver disease etiologies according to initial
MELD-Na score groups (score of 6–20, 21–29, and
≥30). To determine possible differences in disease progression between diseases, patients who received MELD
exception were not included in this analysis.

Prognostic impact of liver transplantation
To assess possible differences in optimal timing of liver
transplantation, intention-to-treat survival was analyzed
in each disease group in patients who did not receive
MELD exceptions. Living donor liver transplantation was
excluded from this analysis. A Cox regression analysis
that modeled liver transplantation as a time-dependent
covariate was created to estimate the prognostic impact
of liver transplantation in each disease group. Patients
were categorized according to final MELD score and
prognostic impact was assessed. Waitlist and post-transplant mortality were considered as endpoints. Patients
removed from waitlist because they were too ill were
considered as mortality. Patients who were removed from
the waitlist due to recovery and other reasons, those who
were still on the waitlist, and those who were alive posttransplant were censored on the last day of follow-up in
this analysis. Risks were adjusted by UNOS regions and
recipient characteristics at the time of removal from waitlist. Donor characteristics were not included in the risk
adjustment because of inclusion of patients who did not
undergo transplantation.

Statistical analysis
Continuous variables were expressed as median with
interquartile range and compared using Kruskal–Wallis
test. Descriptive variables were expressed as proportions
and compared using chi-square test. P values in comparisons between more than two variables were calculated by a Bonferroni correction. Odds ratio was
calculated by logistic regression model. Waitlist outcomes were analyzed using cumulative incidence of
competing events and compared using Gray test. FineGray proportional hazard regression for competing
events was used to compare 90-day and 1-year waitlist
outcomes. Multivariable models to identify risk factors
for waitlist mortality in each disease etiology were performed using Fine-Gray proportional hazard regression
for competing risk events. Prognostic impact of liver
transplantation was assessed using Cox proportional
hazard regression model with time-dependent covariate.
Transplant International 2021; 34: 499–513
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In this model, liver transplantation was modeled as a
time-dependent covariate. Statistical significance was
defined at P value <0.05. All analyses were performed
with SPSS v26 and R v3.2.2.

Results
Based on the inclusion and exclusion criteria, 6094 with
ALD, 1653 with HCV, 3848 with NASH, 602 with PBC,
and 819 with PSC were registered with their laboratory
MELD-Na scores. The rest of patients were granted for
MELD exception. Patient demographics for patients
without MELD exceptions are shown in Table 1.

Comparison of waitlist outcomes between ALD and
each liver disease etiology
Unadjusted cumulative incidence of waitlist outcomes
in patients with the five major liver diseases is shown in
Fig. 1. PBC patients showed the higher mortality rate
(P < 0.001). ALD patients showed the highest transplant
rate (P < 0.001) and highest recovery rate (P < 0.001).

Adjusted risks for waitlist mortality in each liver
disease etiology vs ALD according to MELD-Na score
category
Adjusted hazards of 90-day and 1-year waitlist mortality, transplant, and recovery in HCV, NASH, PBC, and
PSC groups were estimated and compared to the ALD
group (Fig. 2a–c). In comparison to ALD, risk of 90day waitlist mortality was significantly higher in NASH
[adjusted hazard ratio (aHR) 1.20, 95% CI 1.00–1.44,
P = 0.042] and PBC (aHR 1.48, 95% CI 1.08–2.04,
P = 0.02), whereas HCV and PSC had similar risk (aHR
1.06 and 1.27, 95% CI 0.85–1.35 and 0.90–1.81,
P = 0.58 and 0.2, respectively). Ninety-day transplant
probability and recovery were similar between ALD and
other diseases. Adjusted hazards of 1-year waitlist outcomes were assessed (Fig. 2d–f). Overall risk of mortality, compared to ALD, was significantly higher in
NASH (aHR 1.21, 95% CI 1.05–1.39, P = 0.008) and
PBC (aHR 1.52, 95% CI 1.20–1.93, P < 0.001).
When evaluating outcomes according to initial
MELD-Na score categories, PBC with higher scores
showed significantly higher risk of 90-day mortality
(aHR 1.69, 95% CI 1.06–2.68, P = 0.03) and lower 90day transplant probability (aHR 0.68, 95% CI 0.48–0.96,
P = 0.03) than ALD. Because the number of patients
who recovered and were removed from the list in
90 days was very limited, likelihoods of recovery were
501
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Age (year) [IQR]
53.0 [47.0, 60.0]
Age group (%)
<40
703 (11.5)
40–49
1600 (26.3)
50–59
2457 (40.3)
60 or higher
1334 (21.9)
Ethnicity
White
4707 (77.2)
Black
220 (3.6)
Hispanic
917 (15.0)
Others
250 (4.1)
Gender (%)
Male
4260 (69.9)
Female
1834 (30.1)
BMI [IQR]
27.5 [24.2, 31.6]
Diabetes (%)
No
5084 (83.7)
Yes
993 (16.3)
Ascites (%)
None/mild
3702 (60.7)
Moderate/severe
2392 (39.3)
Dialysis (%)
No
5366 (88.1)
Yes
728 (11.9)
Life support requirement (%)
No
2552 (86.8)
Yes
389 (13.2)
Karnofsky score (%)
70–100%
2197 (36.3)
40–60%
2358 (39.0)
10–30%
1492 (24.7)
Encephalopathy (%)
None/mild
5401 (88.6)
Moderate/severe
693 (11.4)
Registered for liver–kidney transplantation
No
5425 (89.0)
Yes
669 (11.0)

ALD
n = 6094
61.0 [55.0, 65.0]
100 (2.6)
461 (12.0)
1348 (35.0)
1939 (50.4)
3051 (79.3)
71 (1.8)
595 (15.5)
131 (3.4)
1910 (49.6)
1938 (50.4)
31.9 [28.0, 36.5]
1581 (41.2)
2256 (58.8)
2510 (65.2)
1338 (34.8)
3468 (90.2)
378 (9.8)
1638 (90.8)
166 (9.2)
1515 (39.9)
1677 (44.2)
604 (15.9)
3553 (92.3)
295 (7.7)
3294 (85.6)
554 (14.4)

54 (3.3)
187 (11.3)
813 (49.2)
599 (36.2)
1027 (62.1)
258 (15.6)
306 (18.5)
62 (3.8)
1077 (65.2)
576 (34.8)
28.1 [24.9, 32.3]
1178 (71.5)
469 (28.5)
1142 (69.1)
511 (30.9)
1403 (84.9)
250 (15.1)
711 (91.4)
67 (8.6)
686 (42.0)
693 (42.4)
254 (15.6)
1520 (92.0)
133 (8.0)
1336 (80.8)
317 (19.2)

NASH
n = 3848

58.0 [54.0, 62.0]

HCV
n = 1653

Table 1. Characteristics of waitlisted patients according to liver disease etiology.

562 (93.4)
40 (6.6)

572 (95.0)
30 (5.0)

295 (50.3)
217 (37.0)
75 (12.8)

589 (97.8)
13 (2.2)

572 (95.0)
30 (5.0)

464 (77.1)
138 (22.9)

495 (82.5)
105 (17.5)

83 (13.8)
519 (86.2)
26.3 [23.2, 30.2]

430 (71.4)
40 (6.6)
108 (17.9)
24 (4.0)

36 (6.0)
108 (17.9)
208 (34.6)
250 (41.5)

58.0 [51.0, 65.0]

PBC
n = 602

(33.0)
(21.6)
(25.3)
(20.1)

790 (96.5)
29 (3.5)

801 (97.8)
18 (2.2)

475 (58.9)
245 (30.4)
87 (10.8)

810 (98.9)
9 (1.1)

801 (97.8)
18 (2.2)

704 (86.0)
115 (14.0)

730 (89.2)
88 (10.8)

557 (68.0)
262 (32.0)
24.9 [22.4, 27.9]

600 (73.3)
134 (16.4)
56 (6.8)
29 (3.5)

270
177
207
165

49.0 [37.0, 59.0]

PSC
n = 819

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

P value
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MELD-Na score [IQR]
MELD-Na group (%)
6–20
21–29
30 or higher
Total bilirubin (mg/dl)
[IQR]
INR [IQR]
GFR (ml/min) [IQR]
CKD stage (%)
Stage 1 or 2 (GFR
60 or higher)
Stage 3 (GFR
30–59)
Stage 4 or 5
(GFR < 30)
Serum sodium level (%)
Normal (135–
145 mmol/l)
Mild hyponatremia
(130–134 mmol/l)
Severe
hyponatremia
(<130 mmol/l)
Hypernatremia
(>145 mmol/l)

Table 1. Continued.

20 [14, 25]
877 (53.1)
533 (32.2)
243 (14.7)
2.4 [1.3, 4.4]
1.46 [1.20, 1.90]
65.6 [33.8, 93.9]
911 (56.0)
358 (22.0)
357 (22.0)

1084 (65.6)
389 (23.5)
166 (10.0)

14 (0.8)

2457 (40.3)
1933 (31.7)
1704 (28.0)
4.1 [2.1, 9.8]
1.63 [1.40, 2.20]
68.9 [40.9, 96.8]
3573 (59.6)
1439 (24.0)
978 (16.3)

3356 (55.1)
1729 (28.4)
939 (15.4)

69 (1.1)

HCV
n = 1653

23 [17, 30]

ALD
n = 6094

Transplant International 2021; 34: 499–513
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31 (0.8)

404 (10.5)

961 (25.0)

2452 (63.7)

666 (17.7)

1187 (31.5)

1915 (50.8)

1.50 [1.30, 1.80]
59.8 [37.5, 87.8]

2140 (55.6)
1095 (28.5)
613 (15.9)
2.6 [1.6, 4.8]

19 [15, 26]

NASH
n = 3848

5 (0.8)

63 (10.5)

167 (27.7)

367 (61.0)

55 (9.2)

145 (24.3)

396 (66.4)

1.30 [1.20, 1.62]
75.8 [50.1, 99.8]

357 (59.3)
171 (28.4)
74 (12.3)
4.7 [2.3, 9.7]

19.0 [14.0, 24.0]

PBC
n = 602

5 (0.6)

54 (6.6)

154 (18.8)

606 (74.0)

40 (4.9)

89 (11.0)

683 (84.1)

1.30 [1.10, 1.60]
102.2 [73.8, 132.2]

514 (62.8)
208 (25.4)
97 (11.8)
5.9 [2.5, 12.6]

18.0 [13.0, 24.0]

PSC
n = 819

<0.001

<0.001

<0.001
<0.001

<0.001

<0.001

<0.001

P value
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Figure 1 Cumulative incidence curves showing (a) waitlist mortality, (b) transplant probability, and (c) recovery on waitlist among ALD, HCV,
NASH, PBC, and PSC patients (Gray test).

Figure 2 Forest plots summarizing adjusted hazards of 90-day and 1-year waitlist outcomes in ALD, HCV, NASH, PBC, and PSC, compared to
ALD. The numbers and subscripts show hazard ratio and 95% confidence interval.

not compared between ALD and other etiology groups
(Fig. 3a).
A significantly higher risk of 1-year mortality was
found in NASH with lower (aHR 1.30, 95% CI 1.01–
1.67, P = 0.042) and mid-scores (aHR 1.35, 95% CI
1.08–1.68, P = 0.008), and in PBC with lower and
higher scores (aHR 1.54 and 1.69, 95% CI 1.04–2.29
504

and 1.09–2.63, P = 0.042 and 0.02), compared to ALD
in respective score groups. In the lower score group, 1year transplant probability was significantly higher in
HCV (aHR 1.76, 95% CI 1.50–2.07, P < 0.001), NASH
(aHR 1.38, 95% CI 1.21–1.57, P < 0.001), PBC (aHR
1.56, 95% CI 1.24–1.97, P < 0.001), and PSC (aHR
1.57, 95% CI 1.29–1.91, P < 0.001) than in ALD.
Transplant International 2021; 34: 499–513
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Figure 3 Forest plots summarizing adjusted hazards of (a) 90-day and (b) 1-year waitlist outcomes (i. Mortality, ii. Transplant, iii. Recovery),
categorized by initial MELD-Na score, between ALD (ref.) and other liver disease (HCV, NASH, PBC, and PSC; *P < 0.05, **P < 0.01,
***P < 0.001, Fine-Gray proportional hazard model).

Likelihood of 1-year recovery was significantly lower in
the NASH (aHR 0.42, 95% CI 0.24–0.73, P = 0.002),
PBC (aHR 0.22, 95% CI 0.05–0.88), P = 0.03), and PSC
patients (aHR 0.06, 95% CI 0.01–0.48, P < 0.001) than
ALD. In the higher score group, PBC showed significantly lower 1-year transplant probability than ALD
(aHR 0.69, 95% CI 0.50–0.97, P = 0.03; Fig. 3b).
Transplant International 2021; 34: 499–513
ª 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd

Risk factors for waitlist mortality in each liver disease
Risk factors for 90-day and 1-year waitlist mortality in
each etiology were identified by multivariable Fine-Gray
models (Table S1 and Table 2). In ALD, older age
groups (40–59, 50–59, 60 years or older), compared to
those <40 years, showed significantly higher risk of 90505
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day and 1-year mortality. Lower Karnofsky scores (10–
30% and 40–60%) were risk factors for 90-day and/or
1-year mortality across all diseases. Among factors comprising the MELD-Na score, kidney dysfunction (CKD
stage 3 or higher) and hyponatremia were significantly
associated with mortality in ALD, HCV, and NASH.
Higher serum total bilirubin level was an independent
risk factor for 90-day mortality in PSC and PBC.
Hyponatremia was an independent risk factor for 90day and 1-year mortality in PSC.

Co-existing conditions according to MELD-Na score
at listing in each liver disease group
Dialysis requirement, status of grade 3 or 4
encephalopathy and moderate ascites at listing were
assessed in each disease group according to the initial
MELD-Na score. In the higher MELD-Na score group,
a rate of dialysis requirement in NASH patients was
highest of all disease groups (38%, P = 0.001). While
dialysis requirement in PBC patients was less likely than
other diseases in all score categories, an increasing risk
of dialysis requirement from the mid to higher MELDNa score groups was more prominent [from 2.3% to
35.1%, odds ratio (OR) 22.62, 95% CI 7.52–67.97],
compared to other disease groups (Fig. 4a). PSC
patients, compared to other disease groups, showed
lower rates of grade 3 or 4 encephalopathy and moderate ascites in all score categories (Fig. 4b,c).

Comparisons of disease progression between liver
disease etiologies
In the lower MELD-Na score group, NASH patients
had significantly higher 90-day delta MELD-Na [0.61,
IQR (0, 3.27)] than ALD [0, IQR ( 0.55, 1.81),
P < 0.001], HCV [0, IQR (0, 1.96), P < 0.001], PBC [0,
IQR (0, 2.1), P < 0.001], and PSC patients [0, IQR (0,
2.5), P = 0.008]. Delta MELD-Na > 5/month was
observed in 3.2% in ALD patients which was significantly lower than in NASH (5.0%, P = 0.01). In the
mid-MELD-Na score group, PBC and PSC patients
showed significantly higher 90-day delta MELD [1.65,
IQR ( 1.8, 7.8)] and 1.91 [ 2.5, 9.3] than ALD [0 IQR
( 3.0, 5.1)] and HCV patients [0, IQR ( 2.6, 4.8)]
(P = 0.003). PBC and PSC patients showed significantly
higher rate of delta MELD > 5/month (15.8% and
14.9%) than ALD (9.7%) and HCV patients (7.5%;
P = 0.001). In the higher MELD-Na score group, 90day delta MELD was similar between disease groups
(Table 3).
506

Prognostic impact of liver transplantation
Intention-to-treat survival was assessed in patients who
were registered with their laboratory MELD-Na score in
each disease group. The positive prognostic impact of
liver transplantation became significant with a MELDNa score category of at least 24–26 in ALD (HR 0.33,
P < 0.001), 18–20 in HCV (HR 0.15, P = 0.004), 15–17
in NASH (HR 0.44, P = 0.02), and 24–26 in PBC and
PSC (HR 0.16 and 0.15, P = 0.02 and 0.02; Fig. 5).

Waitlist outcomes in patients with MELD exception
A total of 4805 patients were granted for MELD exception for HCC, of whom 832, 2950, 922, 46, and 55 were
ALD, HCV, NASH, PBC, and PSC, respectively. Risk of
180-day mortality was significantly higher in HCV and
NASH, compared to ALD. Risk of 1-year waitlist mortality and transplant probability was comparable
between disease groups. There were very few patients
who were removed from the waitlist due to improvement and likelihood of recovery was not able to be
compared between groups (Table 4).
A total of 297 with ALD, 275 with HCV, 330 with
NASH, 66 with PBC, and 298 with PSC were granted
for MELD exceptions for other reasons (non-HCC conditions). In this group, NASH patients showed significantly higher risk of 1-year mortality, compared to ALD
patients. One-year transplant probability was significantly higher in the HCV, PBC, and PSC group, compared to ALD. There was no difference in likelihood of
recovery between disease groups (Table 4).

Discussion
Transplant priority based on MELD and MELD-Na
scores has been the mainstay of liver organ allocation in
the United States since 2002. However, with significant
recent shifts in underlying liver diseases, the ability of
MELD to predict 90-day mortality as declined [10].
This study evaluated different disease progression and
disease-specific waitlist outcomes according to underlying etiologies of liver transplant candidates. Importantly,
unlike the previous studies, we focused on patients registered after implementation of MELD-Na score-based
allocation (January 11, 2016), because waitlist outcomes
have been significantly affected by this allocation change
and because of recent marked shifts in liver diseases
underlying liver transplant in the United States [6]. In
addition, effects of DAA on outcomes in HCV population should be saturated during our study period and
Transplant International 2021; 34: 499–513
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0.48–1.87
0.93–1.54
0.62–1.69
0.90–1.32
0.92–1.74
0.97–1.48

0.84–6.86
1.10–8.34
1.87–14.0
0.99–1.45
Ref
1.46
0.90
0.60
0.80
0.63
1.47

Ref
1.30
1.98
3.03
1.73

0.57–1.53
0.44–1.88
0.16–2.25
0.42–1.53
0.17–.2.36
0.87–2.49

0.21–7.94
0.33–11.75
0.53–17.45
0.68–4.36

95% CI

Ref
0.005 0.99 0.56–1.75
0.059 1.68 0.76–3.68
0.3
2.35 0.61–8.90

0.87
0.17
0.93
0.38
0.15
0.09

0.1
0.03
0.002
0.054

HR

Ref
Ref
0.046 1.96 1.39–2.75 <0.001 1.35 1.10–1.67
0.003 1.68 1.03–2.74
0.08 0.71 0.13–3.78

1.41 1.13–1.77
1.65 0.95–2.87

0.04
0.69

1.31 0.98–1.75
2.04 0.88–4.68

0.07
0.1

0.90 0.42–1.54
0.47 0.03–7.79

Ref
0.005 0.86 0.48–1.54

Ref
Ref
0.16 1.24 0.99–1.55 0.056 2.09 1.25–3.51
0.008 1.58 1.21–2.07 <0.001 0.89 0.36–2.23
0.35 1.16 1.03–1.31 0.01 1.54 0.96–2.46

Ref
1.22 1.00–1.48

Ref
1.32 0.90–1.95
1.77 1.16–2.69
1.12 0.89–1.41

P

PBC

1.02 1.01–1.03 <0.001 1.04 1.01–1.07

0.23
0.02
0.1

0.1

Ref
1.13 0.92–1.39
1.31 1.04–1.65
1.09 0.98–1.21

1.02 0.99–1.04

Ref
0.94
1.19
1.02
1.09
1.27
1.20

Ref
2.39
3.02
5.11
1.20

95% CI

Ref
0.045 1.36 1.09–1.68
0.07 1.37 0.99–1.89
0.02 1.32 0.78–2.24

0.65
0.62
0.86
0.39
0.34
0.98

0.81
0.21
0.16
0.61

HR

0.09

P

NASH

1.01 0.99–1.02

Ref
Ref
1.45 1.16–1.81 0.001 1.45 1.01–2.07
1.89 1.43–2.49 <0.001 1.67 0.96–2.92
1.80 1.33–2.44 <0.001 2.03 1.13–3.67

0.56–1.43
0.74–1.67
0.52–2.21
0.83–1.64
0.78–2.10
0.71–1.42

Ref
0.96–2.07 0.08 0.90
1.10–1.74 0.005 1.11
1.00–2.11 0.048 1.07
0.97–1.47 0.1
1.16
1.23–1.94 <0.001 1.28
0.97–1.38 0.11 1.01

95% CI

Ref
1.41
1.39
1.46
1.19
1.55
1.16

HR

Ref
1.20–2.51 0.003 1.15 0.37–3.6
1.61–3.27 <0.001 1.92 0.69–5.37
2.37–4.94 <0.001 2.11 0.74–6.02
0.93–1.34 0.24 0.92 0.67–1.27

P

HCV

Ref
1.74
2.30
3.42
1.12

95% CI

Statistical significant P values are shown in bold.

Age, years
<40
40–50
51–59
≥60
Gender, female
Race
Caucasian
African American
Hispanic
Others
Diabetes
Grade 3 or 4 encephalopathy
Moderate/severe ascites
Karnofsky score, %
70–100
40–60
10–30
Life support
MELD-Na components
Serum total bilirubin
Chronic kidney disease stage
Stage 1 or 2
Stage 3
Stage 4 or 5
INR
Serum sodium concentration
Normal
Mild to moderate
hyponatremia
Severe hyponatremia
Hypernatremia

HR

ALD

Table 2. Risk factors associated with 1-year waitlist mortality in each liver disease etiology.

0.44–2.33
0.31–4.42
0.53–7.58
0.49–3.10
0.39–.10.37
0.38–2.06

0.32–2.30
0.91–4.84
1.13–7.25
1.24–4.40

95% CI

Ref
0.89 0.43–1.82
4.58 1.42–14.80
1.65 0.12–22.19

Ref
1.01
1.17
2.00
1.23
2.00
0.89

Ref
0.85
2.10
2.87
2.34

HR

0.78
0.6

0.6

2.99 1.26–7.12
—
—

Ref
2.33 1.15–4.71

Ref
0.005 0.62 0.25–1.54
0.81 0.83 0.24–2.88
0.07 0.94 0.63–1.39

0.004 1.02 0.98–1.06

0.98
0.2
0.21

0.51
0.79
0.45
0.51
0.50
0.15

0.78
0.45
0.21
0.25

P

PSC

0.01
—

0.02

0.3
0.77
0.76

0.24

0.74
0.01
0.71

0.98
0.82
0.62
0.66
0.41
0.31

0.75
0.08
0.03
0.009

P
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Figure 4 Co-existing conditions at listing according to liver diseases and initial MELD-Na score categories. (a) Dialysis requirement. (b) Presence
of grade 3 or 4 encephalopathy. (c) Presence of moderate ascites. Tables show odds ratio and 95% confidence interval of each condition in
the mid-MELD-Na score group, compared to the lower MELD-Na score group, and in the higher MELD-Na score group, compared to the midMELD-Na score group. Increasing risks for all comparisons were significant (P < 0.001), except for the risk of dialysis requirement between the
lower and mid-score groups in PSC and the risk of grade 3 or 4 encephalopathy between mid to higher score groups in PBC.

better reflect the current clinical practice, compared to
previous studies [11]. Our study showed that each
major liver disease had different disease progression
depending on MELD-Na scores. NASH patients in the
lower (score of 6–20) and mid (score of 21–30) MELDNa score groups showed faster disease progression
which was represented by significantly higher 90-day
delta MELD-Na score, compared to ALD, HCV, PBC,
and PSC in the comparable score category groups. This
may account for the differences in waitlist outcomes
between disease groups found in this study. Compared
to ALD patients, NASH patients had higher risk of
mortality and lower chance of recovery in the lower to
mid-score categories. Abstinence in transplant candidates with ALD and eradication of HCV in infected
patients could stabilize or improve liver function in
those patients. These disease-specific characteristics
might lead to the discrepancies in disease progression
and waitlist outcomes. Wong et al. [12] evaluated disease-specific waitlist outcomes in patients who were registered from 2004 to 2013 in the United States. They
showed that, compared to patients with NASH, the risk
of 1-year waitlist mortality was significantly higher in
patients with HCV and lower in those with ALD. The
waitlist outcomes in HCV patients reported in their
study should be carefully interpreted, because data used
508

in their study were from pre-DAA era. Further, waitlist
outcomes were not compared according to their MELD
scores. The results of our study suggest an increasing
importance of risk stratification and priority of liver
allocation that considers underlying liver disease.
Higher delta MELD (MELD-Na) indicates rapid disease progression. It was reported that Delta MELD of 5
or higher per month was associated with higher waitlist
mortality [8,9]. Difference of delta MELD-Na between
diseases was more prominent in the lower and midMELD-Na score groups. 90-day delta MELD-Na was
smaller in ALD than NASH, which indicates that disease
was more stable in ALD than NASH. PBC and PSC
patients with a lower MELD-Na score also showed relatively stable MELD-Na score after listing. 90-day delta
MELD in PBC and PSC was similar to ALD and HCV
with a lower MELD-Na score, whereas those patients
with a mid-MELD-Na score showed the highest delta
MELD-Na and delta MELD-Na > 5/month was most
frequently observed among disease groups. These results
suggest that disease progression in PBC and PSC
patients may be accelerated when severity of disease
exceeds a certain level.
Another important finding of this study is different
thresholds of MELD-Na score associated with a positive
prognostic impact of liver transplantation among the
Transplant International 2021; 34: 499–513
ª 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd

65 (2.7)
87 (4.8)
28 (1.1)
0 [ 0.6, 1.8]
78 (3.2)
142 (8.1)
220 (19.0)
127 (7.2)
0 [ 3.0, 5.1]
188 (9.7)
212 (16.4)
191 (26.3)
234 (20.1)
0 [ 7.6, 12.0]
123 (7.2)

Encephalopathy, n (%)*
Ascites, n (%)†
Dialysis, n (%)‡
90-day Delta MELD-Na§
Delta MELD-Na >5/month§
Encephalopathy, n (%)*
Ascites, n (%)†
Dialysis, n (%) s‡
90-day Delta MELD-Na§
Delta MELD-Na >5/month§
Encephalopathy, n (%)*
Ascites, n (%)†
Dialysis, n (%)‡
90-day Delta MELD-Na§
Delta MELD-Na >5/month§

Lower
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31 (3.7)
47 (6.8)
8 (0.9)
0 [0, 2.0]
25 (2.9)
31 (6.4)
53 (16.2)
22 (5.5)
0 [ 2.6, 4.8]
40 (7.5)
38 (20.3)
42 (35.6)
40 (25.3)
0.99 [ 6.8, 18.4]
21 (8.6)

HCV
73 (3.6)
86 (5.3)
25 (1.2)
0.61 [0, 3.3]
107 (5.0)
108 (10.9)
127 (20.5)
86 (9.0)
0.83 [ 2.8, 6.7]
124 (11.3)
98 (18.9)
55 (21.1)
96 (25.3)
2.47 [ 6.5, 14.3]
53 (8.6)

NASH

Delta MELD-Na was calculated in patients who were listed at least for 14 days.

Including patients who did not require dialysis at waitlist registration.

Including patients who did not have moderate ascites at waitlist registration.

Statistical significant P values are shown in bold.

§

‡

†

* Including patients who did not have grade 3 or 4 encephalopathy at waitlist registration.

Higher

Mid

ALD

Newly developed condition

MELD-Na
11 (3.2)
10 (3.2)
4 (1.1)
0 [0, 2.1]
15 (4.2)
20 (12.5)
16 (13.8)
14 (8.4)
1.65 [ 1.8, 7.8]
29 (17.0)
12 (18.8)
8 (20.5)
12 (25.0)
6.75 [ 4.9, 24.6]
10 (13.5)

PBC

Table 3. Clinical deterioration in 90 days after waitlist registration according to liver disease etiologies and MELD-Na score.

14 (2.8)
15 (3.2)
5 (1.0)
0 [0, 2.5]
18 (3.5)
19 (9.2)
21 (12.4)
13 (6.3)
1.91 [ 2.5, 9.3]
31 (14.9)
22 (11.5)
16 (26.2)
16 (19.3)
0 [ 6.9, 12.9]
10 (10.3)

PSC

0.49
0.04
0.98
<0.001
0.01
0.01
0.07
0.21
0.003
0.001
0.29
0.048
0.17
0.32
0.22

P value
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Figure 5 Prognostic impact of liver transplantation in (a) ALD, (b) HCV, (c) NASH, (d) PBC, and (e) PSC. Lower and higher hazard ratios refer
positive and negative prognostic impact of liver transplantation.

five liver disease groups. Survival benefit of liver transplantation has been studied by our group and others,
with the finding that the threshold MELD-Na score
associated with survival benefit is 21 [6,13]. However,
previous studies did not distinguish liver disease etiology. Both waitlist and post-transplant outcomes may
differ as a function of liver disease [14]. Thresholds of
MELD-Na score associated with a positive prognostic
impact of liver transplantation were higher in ALD and
CLD and lower in NASH. These results indicate that
the optimal timing of liver transplantation might be different according to underlying liver disease. While the
results should not be interpreted to mean that liver
transplantation be done only for those above the
MELD-Na score thresholds, the findings do support the
concept of disease-specific priority in liver allocation.
Abstinence removes the hepatic insult in ALD
patients which may explain the higher waitlist recovery
rate in ALD, compared to other liver diseases. Interestingly, ALD had the lowest transplant probability in the
lower score category. This may be associated with slow
disease progression in this population. Giard et al.
recently compared waitlist outcomes between ALD and
non-ALD populations from 2002 to 2016 [5], and also
found superior waitlist outcomes and higher rates of
recovery in liver transplant candidates with ALD. We
focus on more detailed disease progression during waiting time and waitlist outcomes for all five major liver
disease populations and evaluate the prognostic impact
of liver transplantation for each etiology. As noted, our
study focused on patients registered after implementation of MELD-Na score-based allocation (January 11,
2016). Our study showed that hyponatremia was more
prominently associated with poor waitlist outcomes in
510

ALD and HCV (Table 2 and Table S1). The introduction of MELD-Na based allocation might impact their
waitlist outcomes differently. To reflect our current
waitlist practice, findings shown in this study using
more contemporary data would be more reliable.
With the introduction of DAA as curative therapy for
HCV, liver transplant in HCV infected patients offers
longer graft survival compared to the past [15]. While
the number of waitlisted patients with HCV has
decreased because of DAA therapy [15,16], this study
demonstrates that HCV patients with lower MELD-Na
scores have a higher chance of recovery without transplantation, compared to those with NASH or CLD, and
have comparable waitlist outcomes to ALD. Similar to
the effects of abstinence in ALD, eradication of virus in
HCV patients may lead to a decrease in waitlist mortality and an increase in recovery. It should be noted that
data for DAA usage in HCV is not available in the
OPTN/UNOS registry and the succinct impact of DAA
therapy on waitlist outcomes remains to be elucidated.
HCV remains the leading underlying disease for
transplantation for HCC [17]. Our study evaluated
patients with HCC separately and revealed that 180-day
mortality risk was significantly higher in HCV and
NASH than ALD, whereas there was no significant difference in 1-year waitlist outcomes. Patients awaiting
transplant for HCC population have already been subject to disease-specific risk stratification and allocation
with being given an exception score for HCC [18]. It
should be acknowledged that Younossi et al. [19] also
evaluated waitlist dropout rate in the HCC population
between NASH, ALD, HCV, and hepatitis B infection
and showed that waitlist dropout rates were similar
between groups. Liver transplant candidates with HCC
Transplant International 2021; 34: 499–513
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Table 4. Comparisons of waitlist outcomes in patients
with MELD exception for HCC and non-HCC (Ref. ALD).
HR (95% CI)
HCC exception group
180-day mortality
HCV
1.28 (0.94–1.74)
NASH
1.09 (0.75–1.57)
PBC
1.35 (0.48–3.75)
PSC
0.25 (0.03–1.91)
1-year mortality
HCV
0.07 (0.87–1.32)
NASH
0.90 (0.69–1.16)
PBC
1.25 (0.63–2.45)
PSC
0.55 (0.23–1.30)
180-day transplant probability
HCV
1.43 (1.11–1.85)
NASH
1.35 (1.01–0.39)
PBC
1.37 (0.53–3.52)
PSC
1.01 (0.39–2.60)
1-year transplant probability
HCV
1.05 (0.92–1.18)
NASH
1.05 (0.91–1.21)
PBC
0.75 (0.45–1.24)
PSC
1.06 (0.75–1.50)
Non-HCC exception group
90-day mortality
HCV
0.99 (0.38–2.57)
NASH
1.76 (0.80–3.87)
PBC
1.57 (0.07–4.75)
PSC
1.01 (0.38–2.68)
1-year mortality
HCV
1.28 (0.75–2.19)
NASH
1.98 (1.20–3.28)
PBC
1.42 (0.56–3.60)
PSC
0.96 (0.54–1.72)
90-day transplant probability
HCV
1.52 (1.04–2.25)
NASH
0.68 (0.46–0.99)
PBC
0.85 (0.44–1.64)
PSC
1.24 (0.82–1.86)
1-year transplant probability
HCV
1.33 (1.02–1.74)
NASH
1.01 (0.80–1.29)
PBC
1.00 (0.66–1.51)
PSC
1.55 (1.19–2.01)
90-day recovery
Incalculable
1-year recovery
HCV
0.27 (0.04–1.69)
NASH
0.29 (0.07–1.11)
PBC
0.34 (0.03–3.56)
PSC
0.34 (0.06–1.82)

P value

0.11
0.66
0.57
0.18
0.54
0.42
0.52
0.17
0.006
0.04
0.52
0.98
0.48
0.053
0.26
0.73

0.99
0.16
0.6
0.99
0.37
0.008
0.46
0.9
0.03
0.047
0.62
0.31
0.04
0.91
0.001
<0.001

0.16
0.07
0.37
0.21

Statistical significant P values are shown in bold.

usually have a very low MELD score and difference of
disease progression among disease etiologies might not
be obvious. It was reported that oncological features
Transplant International 2021; 34: 499–513
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were different according to underlying liver disease,
which might be associated with the difference in waitlist
outcomes at 180 days [20].
NASH patients showed higher mortality and lower
chance of recovery, compared to ALD patients. In
patients who were granted MELD exception for nonHCC reasons, NASH had significantly higher risk of 1year mortality compared to ALD. According to our
findings, NASH patients are significantly older than
other disease groups with over 50% of waitlisted
patients being 60 years or older. Of note, older patients
have a significantly higher risk of waitlist mortality.
Because the NASH group has the largest number of
older patients, the impact of older age on waitlist outcomes in NASH would be more prominent than in
other disease groups [14]. Currently, liver allocation in
the United States does not take patient age into
account. It would not be straightforward to incorporate
patient age into the allocation system. Allocation of priority to older patients should be carefully considered
based on individual risk and benefit of liver transplantation, because older recipient age is a well-known risk
factor for post-transplant mortality [14].
When assessing waitlist mortality in the entire group,
PBC patients showed the highest risk of waitlist mortality. Interestingly, PSC patients showed the lowest mortality rate among the disease groups, though the
difference was not significant after risk adjustment.
Although these two diseases may be classified in the
same disease category as cholestatic liver disease, disease
progression may be quite different between PBC and
PSC. In fact, the lower risk of waitlist mortality in PSC
patients was reported by other groups [21]. Goldberg
et al. [22] reported that patients with PSC were less
likely to develop complications of portal hypertension,
compared to non-PSC patients, which might contribute
to the lower risk of waitlist mortality in this group. Our
study also revealed that the rates of grade 3 or 4
encephalopathy and moderate ascites at listing were
lowest in PSC patients than other disease groups
(Fig. 4). However, we should acknowledge that both
PBC and PSC patients had higher delta MELD-Na than
ALD, HCV, or NASH in the mid-MELD-Na score category. In addition, the increased risk of waitlist mortality
in PBC and PSC patients with a higher MELD-Na score
was observed, compared with HCV, NASH or ALD
(Fig. 3). Given the worse waitlist outcomes in these
populations especially in the higher MELD-Na score
category, PBC and PSC patients are at a potential disadvantage in the current MELD-Na-based allocation system. In this population, rapid deterioration more likely
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occurs when their MELD-Na scores reach mid to higher
score range. Given the unique disease progression, it
may be important to carefully monitor their MELD-Na
score and co-morbidities in this particular population.
Acute-on-chronic liver failure might be associated with
their poor outcomes, though the OPTN/UNOS registry
does not contain sufficient information to identify
patients who developed acute-on-chronic liver failure.
Their disease status and prognosis may need to be
assessed not only by MELD-Na score, but also other
models such as the updated Mayo PBC risk score,
which is calculated by total bilirubin, prothrombin time,
age, albumin, presence of peripheral edema, and
requirement of diuretics [23,24].
Limitations of this study include its retrospective nature and usage of the OPTN/UNOS registry which lacks
some detailed clinical data, specifically abstinent period,
relapse of alcohol pre- and post-transplant, psychosocial
status, and DAA usage. Secondly, we included only
diagnosis of “alcoholic cirrhosis” as ALD. Because of
the increasing interests in liver transplantation for alcoholic hepatitis, waitlist outcomes in this population
remain to be elucidated. We acknowledge that it is
likely that some alcoholic hepatitis patients were classified as “alcoholic cirrhosis” in the database.
In conclusion, liver transplant candidates with major
liver diseases showed different disease progression during their waiting time. ALD and HCV patients show relatively slower disease progression, whereas it may
progress faster in NASH. PBC and PSC patients may
show rapid deterioration of condition when their
MELD-Na score reaches mid to higher rage. These differences lead to the discrepancies in waitlist outcomes
between disease groups. ALD patients have lower mortality risk, better recovery chance on waitlist, and NASH
and PBC patients have worse waitlist outcomes in particular MELD-Na score categories. The unique characteristics in each liver disease may need to be considered
in the assessment of medical urgency. The findings

suggest that risk stratification and priority of liver allocation might need to be altered according to liver disease etiology.
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